Discontinued

August 1, 2001
Kevin Gopal
Kevin Gopal

Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-08-01-2001, Volume 0, Issue 0

London/Sodertalje—AstraZeneca’s decision to drop Viozan (AR-C68397AA) for chronic obstructive pulmonary disease (COPD) could be GlaxoSmithKline’s gain.

Related Content:

News